What is Stenotrophomonas maltophilia?

What is Stenotrophomonas maltophilia?​

Stenotrophomonas (Xanthomonas) maltophilia is a multidrug-resistant gram-negative bacillus that is an opportunistic pathogen [1-4], particularly among hospitalized patients. S. maltophilia infections have been associated with high morbidity and mortality in severely immunocompromised and debilitated individuals.

What is the treatment for Stenotrophomonas maltophilia meningitis (SMM)?​

What is the treatment for Stenotrophomonas maltophilia meningitis (SMM)?
Successful treatment of multi-resistant Stenotrophomonas maltophilia meningitis with ciprofloxacin in a pre-term infant. Eur J Pediatr 2002; 161:680.

Can matrix-assisted laser desorption/ionization identify Stenotrophomonas maltophilia?​

Matrix-assisted laser desorption/ionization (MALDI) identification of Stenotrophomonas is not yet standard for many microbiology laboratories. S. maltophilia was first isolated in 1943 and, at the time, was named Bacterium bookeri.

What is the history of Pseudomonas maltophilia?​

What is the history of Pseudomonas maltophilia?
S. maltophiliawas first isolated in 1943 as Bacterium bookeriand then named Pseudomonas maltophilia(154); later, rRNA cistron analysis determined that it was more appropriately named Xanthomonas maltophilia(259, 260, 325).
Stenotrophomonas maltophilia is an emerging multi-drug-resistant global opportunistic pathogen.

What are the treatment options for Stenotrophomonas infections?​

Polymyxin B may be effective treatment, at least in vitro, though not without frequent adverse effects. Stenotrophomonas infections have been associated with high morbidity and mortality in severely immunocompromised and debilitated individuals.

Is Staphylococcus maltophilia a nosocomial pathogen?​

Is Staphylococcus maltophilia a nosocomial pathogen?
In immunocompromised patients, S. maltophilia can lead to nosocomial infections. It is also an emerging nosocomial pathogen associated with opportunistic infections in patients with cystic fibrosis, cancer, and HIV.

Stenotrophomonas maltophilia, previously known as Pseudomonas maltophilia, is a multidrug-resistant gram-negative bacillus that can cause infections, especially in hospitalized patients. It is considered an opportunistic pathogen and has been linked to high morbidity and mortality rates in individuals who are severely immunocompromised or debilitated.

Regarding the treatment of Stenotrophomonas maltophilia meningitis (SMM), there have been cases where successful treatment was achieved with ciprofloxacin, as reported in a study involving a pre-term infant in 2002.

Matrix-assisted laser desorption/ionization (MALDI) identification of Stenotrophomonas is not yet a standard practice in many microbiology laboratories. Despite being first isolated in 1943 under the name Bacterium bookeri, its current name Stenotrophomonas maltophilia was confirmed later through rRNA cistron analysis, emphasizing its emergence as a multi-drug-resistant global opportunistic pathogen.

Treatment options for Stenotrophomonas infections include the use of Polymyxin B, which has shown effectiveness in vitro, albeit with frequent adverse effects. Infections caused by Stenotrophomonas are concerning due to their association with high morbidity and mortality rates, particularly in severely immunocompromised individuals.

Lastly, it is important to clarify that Stenotrophomonas maltophilia, not Staphylococcus maltophilia, is the nosocomial pathogen of concern. In immunocompromised individuals, S. maltophilia can lead to nosocomial infections, making it an emerging pathogen associated with opportunistic infections in patients with conditions like cystic fibrosis, cancer, and HIV.